{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:58:11Z","timestamp":1779886691363,"version":"3.53.1"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Myasthenia gravis (MG) patients are highly susceptible to community-acquired pneumonia (CAP) due to the need for immunosuppressive therapies and aspiration risks, with CAP representing the leading infectious cause of mortality in this population. The intersection of MG and CAP poses unique challenges for the management of anti-infective agents and immunosuppressants. There is currently no systematic literature review addressing these issues, as previous reviews have been limited to one of these aspects. This review synthesizes evidence on the pharmacotherapeutic challenges associated with MG-CAP comorbidity, focusing on three key areas: avoiding antibiotics that exacerbate neuromuscular junction symptoms, minimizing drug interactions, and managing infection-adjusted immunosuppressants. Through a comprehensive synthesis of literature, we provide recommendations for optimizing antibiotic selection and immunosuppressants while tailoring immunosuppressive strategies according to CAP severity grading. This facilitates optimal management of both MG and infection control, highlighting the need for dynamic, patient-centered approaches. This clinical decision-making tool serves as a practical reference for physicians in the absence of established guidelines or expert consensus for managing this complex patient population.<\/jats:p>","DOI":"10.3389\/fphar.2025.1695526","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:30:32Z","timestamp":1763015432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis and community-acquired pneumonia: therapeutic challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00228-022-03349-4","article-title":"A rare side effect due to voriconazole: myasthenia gravis","volume":"78","author":"Akcam","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/mus.26918","article-title":"COVID-19 in patients with myasthenia gravis","volume":"62","author":"Anand","year":"2020","journal-title":"Muscle Nerve"},{"key":"B4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/medicina57050435","article-title":"The management of immunosuppression in kidney transplant recipients with COVID-19 disease: an update and systematic review of the literature","volume":"57","author":"Angelico","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archneur.1986.00520030045010","article-title":"Ampicillin may aggravate clinical and experimental myasthenia gravis","volume":"43","author":"Argov","year":"1986","journal-title":"Arch. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/psp4.12275","article-title":"Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug\u2012drug interactions: CYP3A\/2C9 induction and OATP inhibition effects","volume":"7","author":"Asaumi","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/mus.22077","article-title":"Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance","volume":"43","author":"Auriel","year":"2011","journal-title":"Muscle Nerve"},{"key":"B8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mus.23751","article-title":"Exacerbation of myasthenia gravis with voriconazole","volume":"47","author":"Azzam","year":"2013","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000109410","article-title":"Development of Myasthenia gravis due to treatment of chronic hepatitis C with a combination of interferon-alpha and ribavirin","volume":"75","author":"Bektas","year":"2007","journal-title":"Digestion"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1053\/j.gastro.2020.11.045","article-title":"Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA\/ELTR multi-center European study","volume":"160","author":"Belli","year":"2021","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jemermed.2015.04.019","article-title":"Emergency department management of a Myasthenia gravis patient with community-acquired pneumonia: does initial antibiotic choice lead to cure or crisis?","volume":"50","author":"Berkel","year":"2016","journal-title":"J. Emerg. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"20406223221122538","DOI":"10.1177\/20406223221122538","article-title":"Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort","volume":"13","author":"Bi","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.autrev.2011.10.015","article-title":"Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment","volume":"11","author":"Bijl","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug\u2012drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann","year":"2022","journal-title":"Lancet Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.27324","article-title":"COVID-19 in patients with myasthenia gravis: epidemiology and disease course","volume":"64","author":"Businaro","year":"2021","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","article-title":"2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia","volume":"52","author":"Chaudhuri","year":"2024","journal-title":"Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2282182","DOI":"10.1080\/07853890.2023.2282182","article-title":"Latent tuberculosis infection in myasthenia gravis patients on immunosuppressive therapy: high incidence yet moderate reactivation rate","volume":"55","author":"Chen","year":"2023","journal-title":"Ann. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1439-0507.2008.01524.x","article-title":"Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity","volume":"51","author":"Christopeit","year":"2008","journal-title":"Mycoses"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1293626","DOI":"10.3389\/fneur.2023.1293626","article-title":"Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy","volume":"14","author":"Crescioli","year":"2023","journal-title":"Front. Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm1242","article-title":"Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice","volume":"11","author":"Davies","year":"2005","journal-title":"Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/bja\/50.3.251","article-title":"Tobramycin and neuromuscular transmission in the rat isolated phrenic nerve-diaphragm preparation","volume":"50","author":"de Rosayro","year":"1978","journal-title":"Br J Anaesth"},{"key":"B25","first-page":"233","article-title":"Effect of different kinds of antibiotics on transmission function at neuromuscular junction in mice with myasthenia gravis","volume":"9","author":"Deng","year":"2005","journal-title":"Chin. J. Clin. Rehab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2","volume":"7","author":"Devresse","year":"2022","journal-title":"Kidney Intl Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/TP.0000000000004394","article-title":"Nirmatrelvir\/ritonavir use with tacrolimus in lung transplant recipients: a single-center case series","volume":"107","author":"Dewey","year":"2023","journal-title":"Transplantation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/cid\/ciy723","article-title":"Prevalence and etiology of community-acquired pneumonia in immunocompromised patients","volume":"68","author":"Di Pasquale","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/ard.2010.144741","article-title":"The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case\u2012control study","volume":"70","author":"Dixon","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nmd.2024.03.010","article-title":"Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis","volume":"38","author":"Dodd","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"106614","DOI":"10.1016\/j.ijantimicag.2022.106614","article-title":"Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses","volume":"60","author":"Domingos","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/acn3.51746","article-title":"Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis","volume":"10","author":"Fan","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/ene.15348","article-title":"Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience","volume":"29","author":"Farina","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.nmd.2004.01.005","article-title":"Competitive and open channel block of recombinant nAChR channels by different antibiotics","volume":"14","author":"Friedrich","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejphar.2015.06.004","article-title":"Oseltamivir produces hypothermic and neuromuscular effects by inhibition of nicotinic acetylcholine receptor functions: Comparison to procaine and bupropion","volume":"762","author":"Fukushima","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/mus.27703","article-title":"Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis","volume":"66","author":"Gamez","year":"2022","journal-title":"Muscle Nerve"},{"key":"B39","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.0000000000000186","article-title":"Management and outcome of COVID-19 infection using nirmatrelvir\/ritonavir in kidney transplant patients","volume":"18","author":"Gigu\u00e8re","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","article-title":"Myasthenia gravis, respiratory function, and respiratory tract disease","volume":"270","author":"Gilhus","year":"2023","journal-title":"J. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.neuropharm.2009.07.031","article-title":"Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness","volume":"57","author":"Harnett","year":"2009","journal-title":"Neuropharmacology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/mus.24594","article-title":"Exacerbation of myasthenia gravis by intravenous peramivir","volume":"51","author":"Hayashi","year":"2015","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/IJNRD.S42791","article-title":"Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration","volume":"6","author":"Honore","year":"2013","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"767961","DOI":"10.3389\/fneur.2021.767961","article-title":"Patients with Myasthenia gravis with acute onset of dyspnea: predictors of progression to myasthenic crisis and prognosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/17425255.2023.2193325","article-title":"A critical review of methotrexate clinical interactions: role of transporters","volume":"19","author":"Jafari","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/ene.14951","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","volume":"28","author":"Jakub\u00edkov\u00e1","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1132201","DOI":"10.3389\/fimmu.2023.1132201","article-title":"Knowledge mapping of global trends for myasthenia gravis development: a bibliometrics analysis","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1600-6135.2004.00738.x","article-title":"Immunosuppressive drug interactions with anti-infective agents","volume":"4","author":"Kaufman","year":"2004","journal-title":"Am. J. Transplant."},{"key":"B56","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1177\/08850666241231495","article-title":"Management of immunosuppressive therapy in kidney transplant recipients with sepsis: a multicenter retrospective study","volume":"39","author":"Kim","year":"2024","journal-title":"J. Intensive Care Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The Second International Consensus Guidelines on the management of BK polyomavirus in kidney transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","article-title":"Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"Krenn","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1016\/j.apsb.2022.04.014","article-title":"Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis","volume":"12","author":"Kuang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B60","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"B61","volume-title":"UpToDate Lexidrug: Evidence-Based Drug Referential Content for Teams","year":"2025"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/fcp.12670","article-title":"Aggravation of a myasthenic condition associated with antituberculous drugs: a case with positive rechallenge","volume":"35","author":"Litovsky","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/hematology.2020000116","article-title":"Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases","volume":"2020","author":"Malpica","year":"2020","journal-title":"Hematology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00044011-200424010-00008","article-title":"Impaired rehabilitation secondary to muscle weakness induced by Meropenem","volume":"24","author":"Margolin","year":"2004","journal-title":"Clin. Drug Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ajhp\/zxac343","article-title":"Myasthenia gravis: what does a pharmacist need to know?","volume":"80","author":"Marriott","year":"2023","journal-title":"Am. J. Health Syst Pharm."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1161\/01.STR.0000190056.76543","article-title":"Dysphagia after stroke: incidence, diagnosis, and pulmonary complications","volume":"36","author":"Martino","year":"2005","journal-title":"Stroke"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1341321","DOI":"10.3389\/fimmu.2024.1341321","article-title":"Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study","volume":"15","author":"Mena-V\u00e1zquez","year":"2024","journal-title":"Front. Immunol."},{"key":"B69","volume-title":"Myasthenia gravis foundation of America","year":"2025"},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12941-021-00426-x","article-title":"Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review","volume":"20","author":"Mihevc","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B71","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of Myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e2608","DOI":"10.7759\/cureus.2608","article-title":"The emergence of a forgotten entity: dermatomyositis-like presentation of lyme disease in rural Wisconsin","volume":"10","author":"Novitch","year":"2018","journal-title":"Cureus"},{"key":"B75","volume-title":"Oxford centre for evidence-based medicine","year":"2025"},{"key":"B76","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/jnnp.57.3.383","article-title":"Worsening of myasthenia gravis on treatment with imipenem\/cilastatin","volume":"57","author":"O\u2019Riordan","year":"1994","journal-title":"J. Neurol Neurosurg. Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3109\/0886022X.2012.684513","article-title":"Rhabdomyolysis and severe muscle weakness secondary to colistin therapy","volume":"34","author":"\u00d6zkan","year":"2012","journal-title":"Ren. Fail."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1021\/acschemneuro.9b00041","article-title":"Autoimmune attack of the neuromuscular junction in Myasthenia gravis: nicotinic acetylcholine receptors and other targets","volume":"10","author":"Paz","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mus.27230","article-title":"Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis","volume":"64","author":"Pham","year":"2021","journal-title":"Muscle Nerve"},{"key":"B80","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mus.26032","article-title":"Infections and the relationship to treatment in neuromuscular autoimmunity","volume":"57","author":"Prior","year":"2018","journal-title":"Muscle Nerve"},{"key":"B81","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/microorganisms13010055","article-title":"Real-world effectiveness and safety of isavuconazole versus amphotericin B for patients with invasive mucormycosis","volume":"13","author":"Qin","year":"2025","journal-title":"Microorganisms"},{"key":"B83","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-200520","article-title":"COVID-19 in refractory Myasthenia gravis- A case report of successful outcome","volume":"7","author":"Ramaswamy","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"B85","doi-asserted-by":"publisher","first-page":"ofad565","DOI":"10.1093\/ofid\/ofad565","article-title":"Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes","volume":"10","author":"Ramirez","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12883-022-02922-9","article-title":"Analysis of length of stay and treatment emergent complications in hospitalized myasthenia gravis patients with exacerbation","volume":"23","author":"Ramsaroop","year":"2023","journal-title":"BMC Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/03009742.2020.1732459","article-title":"Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status","volume":"49","author":"Rasmussen","year":"2020","journal-title":"Scand. J. Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/ndt\/gfl539","article-title":"Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients","volume":"22","author":"Rerolle","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cNet State of Immunosuppression.\u201d","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/vaccines9101112","article-title":"COVID-19 vaccination in patients with Myasthenia gravis: a single-center case series","volume":"9","author":"Ruan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transpl. Infect. Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1212\/01.wnl.0000218665.94920.5e","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"66","author":"Sanders","year":"2006","journal-title":"Neurology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s15010-006-5657-8","article-title":"Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients","volume":"34","author":"Saner","year":"2006","journal-title":"Infection"},{"key":"B95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jocn.2023.09.023","article-title":"Clinical features, treatments, their impact, and quality of life for Myasthenia gravis patients in Australia","volume":"118","author":"Sansoni","year":"2023","journal-title":"J. Clin. Neurosci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e002141","DOI":"10.1136\/bmjresp-2023-002141","article-title":"Impact of different corticosteroids on severe community-acquired pneumonia: a systematic review and meta-analysis","volume":"11","author":"See","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The impacts of influenza infection and vaccination on exacerbation of Myasthenia gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J. Clin. Neurol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of Myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J. Clin. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e13134","DOI":"10.1111\/tid.13134","article-title":"Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: a multinational survey","volume":"21","author":"Shepshelovich","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"116520","DOI":"10.1016\/j.jns.2019.116520","article-title":"Hospital admission and prevalence trends of adult myasthenia gravis in Finland in 2004-2014: a retrospective national registry study","volume":"407","author":"Sipil\u00e4","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jinf.2011.07.008","article-title":"Convulsions and apnoea in a patient infected with new Delhi metallo-\u03b2-lactamase-1 Escherichia coli treated with colistin","volume":"63","author":"Spapen","year":"2011","journal-title":"J. Infect."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e13510","DOI":"10.1111\/ctr.13510","article-title":"Interactions between anti-infective agents and immunosuppressants-Guidelines from the American Society of transplantation infectious diseases community of practice","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin. Transpl."},{"key":"B104","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2010.02.016","article-title":"Neuromuscular disorders associated with Hepatitis B vaccination","volume":"292","author":"St\u00fcbgen","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1016728","DOI":"10.3389\/fcimb.2022.1016728","article-title":"Pneumonia in myasthenia gravis: microbial etiology and clinical management","volume":"12","author":"Su","year":"","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"816243","DOI":"10.3389\/fneur.2022.816243","article-title":"Clinical predictors of relapse in a cohort of steroid-treated patients with well-controlled Myasthenia gravis","volume":"13","author":"Su","year":"","journal-title":"Front. Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ebiom.2018.01.007","article-title":"Acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with Myasthenia gravis: a double-blind randomized controlled trial (ProPATIent-Trial)","volume":"28","author":"Tackenberg","year":"2018","journal-title":"EBioMedicine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12883-023-03486-y","article-title":"Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients","volume":"23","author":"Tayebi","year":"2023","journal-title":"BMC Neurol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/14760584.2023.2261785","article-title":"Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature review","volume":"22","author":"Tsoumani","year":"2023","journal-title":"Expert Rev. Vaccines."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s10072-020-04387-5","article-title":"Exacerbation of myasthenia gravis after amoxicillin therapy: a case series","volume":"41","author":"Vacchiano","year":"2020","journal-title":"Neurol. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2024.14796","article-title":"Community-acquired pneumonia: a review","volume":"332","author":"Vaughn","year":"2024","journal-title":"JAMA"},{"key":"B114","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/j.bj.2020.08.010","article-title":"Comparative analysis of the drug\u2012drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis","volume":"44","author":"Wang","year":"2021","journal-title":"Biomed. J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"17562864241226745","DOI":"10.1177\/17562864241226745","article-title":"Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study","volume":"17","author":"Wang","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B116","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","article-title":"Mortality rates and causes of death in Swedish Myasthenia gravis patients","volume":"30","author":"Westerberg","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"B117","doi-asserted-by":"publisher","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B118","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2023.5208","article-title":"SARS-CoV-2 vaccination and neuroimmunological disease: a review","volume":"81","author":"Willison","year":"2024","journal-title":"JAMA Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-022-00646-5","article-title":"Vaccination and immunotherapies in neuroimmunological diseases","volume":"18","author":"Winkelmann","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1070581","DOI":"10.3389\/fpubh.2023.1070581","article-title":"Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: a single-center retrospective cohort study","volume":"11","author":"Wu","year":"2023","journal-title":"Front. Public Health"},{"key":"B121","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jac\/dkl196","article-title":"Pharmacokinetic interaction between methotrexate and piperacillin\/tazobactam resulting in prolonged toxic concentrations of methotrexate","volume":"58","author":"Zarychanski","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","article-title":"Immunotherapy choice and maintenance for generalized myasthenia gravis in China","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12974-021-02298-6","article-title":"Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity","volume":"18","author":"Zhang","year":"2021","journal-title":"J Neuroinflammation"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acn3.51792","article-title":"Mortality of myasthenia gravis: a national population-based study in China","volume":"10","author":"Zhang","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"733418","DOI":"10.3389\/fimmu.2021.733418","article-title":"To be or not to be vaccinated: that is a question in Myasthenia gravis","volume":"1","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21440","article-title":"Safety of influenza vaccination in patients with myasthenia gravis: a population-based study","volume":"40","author":"Zinman","year":"2009","journal-title":"Muscle Nerve"},{"key":"B127","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijid.2021.03.004","article-title":"Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan","volume":"106","author":"Zu","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20471\/acc.2021.60.03.21","article-title":"Treatment of myasthenia gravis patients with Covid-19: review of the literature","volume":"60","author":"\u017dupani\u0107","year":"2021","journal-title":"Acta Clin. Croat."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1695526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:30:34Z","timestamp":1763015434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1695526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":128,"alternative-id":["10.3389\/fphar.2025.1695526"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1695526","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"article-number":"1695526"}}